GT Biopharma (NASDAQ:GTBP – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04), FiscalAI reports.
GT Biopharma Trading Down 0.5%
Shares of NASDAQ GTBP traded down $0.00 during midday trading on Friday, hitting $0.30. The company’s stock had a trading volume of 794,431 shares, compared to its average volume of 1,184,221. The stock has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.42. GT Biopharma has a one year low of $0.26 and a one year high of $1.53. The firm has a market capitalization of $13.12 million, a price-to-earnings ratio of -0.05 and a beta of 0.90.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on GTBP. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a report on Wednesday, July 8th. Wall Street Zen upgraded GT Biopharma to a “hold” rating in a research note on Saturday, June 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.
GT Biopharma Company Profile
GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.
The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).
Featured Articles
- Five stocks we like better than GT Biopharma
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
